Cancer immunogenomics is an emerging field that bridges genomics and immunology. The
establishment of large-scale genomic collaborative efforts along with the development of …

Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …

Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genoty** and longitudinal disease monitoring. However, owing to past emphasis on …

Intratumor heterogeneity provides the fuel for the evolution and selection of subclonal tumor
cell populations. However, accurate inference of tumor subclonal architecture and …

Genome instability and aberrant alterations of transcriptional programs both play important
roles in cancer. Single-cell RNA sequencing (scRNA-seq) has the potential to investigate …

Single-cell barcoding technologies enable genome sequencing of thousands of individual
cells in parallel, but with extremely low sequencing coverage (< 0.05×) per cell. While the …

Abstract Development of candidate cancer treatments is a resource-intensive process, with
the research community continuing to investigate options beyond static genomic …

Treatment failure for the lethal brain tumor glioblastoma (GBM) is attributed to intratumoral
heterogeneity and tumor evolution. We utilized 3D neuronavigation during surgical resection …

The earliest events during human tumour initiation, although poorly characterized, may hold
clues to malignancy detection and prevention. Here we model occult preneoplasia by …

Improved identification of structural variants (SVs) in cancer can lead to more targeted and
effective treatment options as well as advance our basic understanding of the disease and …